Cargando…

The Potential of Senescence as a Target for Developing Anticancer Therapy

Senescence occurs in response to various stimuli. Senescence has attracted attention because of its potential use in anticancer therapy as it plays a tumor-suppressive role. It also promotes tumorigeneses and therapeutic resistance. Since senescence can induce therapeutic resistance, targeting senes...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jo, Hyein, Shim, Kyeonghee, Jeoung, Dooil
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9961771/ https://www.ncbi.nlm.nih.gov/pubmed/36834846 http://dx.doi.org/10.3390/ijms24043436

Ejemplares similares

Cancer/Testis Antigens as Targets for RNA-Based Anticancer Therapy
por: Shim, Kyeonghee, et al.
Publicado: (2023)

Potential of the miR-200 Family as a Target for Developing Anti-Cancer Therapeutics
por: Jo, Hyein, et al.
Publicado: (2022)

Roles of RNA Methylations in Cancer Progression, Autophagy, and Anticancer Drug Resistance
por: Jo, Hyein, et al.
Publicado: (2023)

Targeting HDAC6 to Overcome Autophagy-Promoted Anti-Cancer Drug Resistance
por: Jo, Hyein, et al.
Publicado: (2022)

Exosomes: Diagnostic and Therapeutic Implications in Cancer
por: Jo, Hyein, et al.
Publicado: (2023)

The Crosstalk between FcεRI and Sphingosine Signaling in Allergic Inflammation
por: Jo, Hyein, et al.
Publicado: (2022)

HDAC2 as a target for developing anti-cancer drugs
por: Jo, Hyein, et al.
Publicado: (2023)

Cancer/testis antigen CAGE mediates osimertinib resistance in non-small cell lung cancer cells and predicts poor prognosis in patients with pulmonary adenocarcinoma
por: Yeon, Minjeong, et al.
Publicado: (2023)

Targeting senescence as an anticancer therapy
por: Bousset, Laura, et al.
Publicado: (2022)

Homoharringtonine Inhibits Allergic Inflammations by Regulating NF-κB-miR-183-5p-BTG1 Axis
por: Kim, Misun, et al.
Publicado: (2020)

Role of Senescence in Tumorigenesis and Anticancer Therapy
por: Stoczynska-Fidelus, Ewelina, et al.
Publicado: (2022)

MiR-154-5p-MCP1 Axis Regulates Allergic Inflammation by Mediating Cellular Interactions
por: Kim, Misun, et al.
Publicado: (2021)

Targeting anticancer drug-induced senescence in glioblastoma therapy
por: Tomicic, Maja T., et al.
Publicado: (2018)

Tubulin Beta3 Serves as a Target of HDAC3 and Mediates Resistance to Microtubule-Targeting Drugs
por: Kim, Youngmi, et al.
Publicado: (2015)

Histone Deacetylase Inhibitors to Overcome Resistance to Targeted and Immuno Therapy in Metastatic Melanoma
por: Yeon, Minjeong, et al.
Publicado: (2020)

Exploiting tumor cell senescence in anticancer therapy
por: Lee, Minyoung, et al.
Publicado: (2014)

Targeting Autophagy for Overcoming Resistance to Anti-EGFR Treatments
por: Kwon, Yoojung, et al.
Publicado: (2019)

Senescence in chronic wounds and potential targeted therapies
por: Wei, Xuerong, et al.
Publicado: (2022)

Senescence of Tumor Cells in Anticancer Therapy—Beneficial and Detrimental Effects
por: Piskorz, Wiktoria Monika, et al.
Publicado: (2022)

Senescent T cells: a potential biomarker and target for cancer therapy
por: Zhang, Jie, et al.
Publicado: (2021)

Therapy-Induced Senescence: Opportunities to Improve Anticancer Therapy
por: Prasanna, Pataje G, et al.
Publicado: (2021)

Histone Deacetylase-3/CAGE Axis Targets EGFR Signaling and Regulates the Response to Anti-Cancer Drugs
por: Kim, Hyuna, et al.
Publicado: (2016)

miR-335 Targets SIAH2 and Confers Sensitivity to Anti-Cancer Drugs by Increasing the Expression of HDAC3
por: Kim, Youngmi, et al.
Publicado: (2015)

The Potential of Combining Tubulin-Targeting Anticancer Therapeutics and Immune Therapy
por: Fong, Alexis, et al.
Publicado: (2019)

Role of HDAC3-miRNA-CAGE Network in Anti-Cancer Drug-Resistance
por: Kwon, Yoojung, et al.
Publicado: (2018)

Correction to: Therapy-Induced Senescence: Opportunities to Improve Anticancer Therapy
Publicado: (2022)

Lysosomes as a Target of Anticancer Therapy
por: Trybus, Wojciech, et al.
Publicado: (2023)

Apoptosis: A Target for Anticancer Therapy
por: Pfeffer, Claire M., et al.
Publicado: (2018)

RAD52 as a Potential Target for Synthetic Lethality-Based Anticancer Therapies
por: Toma, Monika, et al.
Publicado: (2019)

FcεRI-HDAC3-MCP1 Signaling Axis Promotes Passive Anaphylaxis Mediated by Cellular Interactions
por: Kim, Misun, et al.
Publicado: (2019)

Recent developments in receptor tyrosine kinases targeted anticancer therapy
por: Raval, Samir H., et al.
Publicado: (2016)

Monoamine Oxidase (MAO) as a Potential Target for Anticancer Drug Design and Development
por: Aljanabi, Reem, et al.
Publicado: (2021)

DDX53 Promotes Cancer Stem Cell-Like Properties and Autophagy
por: Kim, Hyuna, et al.
Publicado: (2017)

DDX53 Regulates Cancer Stem Cell-Like Properties by Binding to SOX-2
por: Kim, Youngmi, et al.
Publicado: (2017)

The CAGE–MiR-181b-5p–S1PR1 Axis Regulates Anticancer Drug Resistance and Autophagy in Gastric Cancer Cells
por: Yeon, Minjeong, et al.
Publicado: (2021)

Glucose Transporters as a Target for Anticancer Therapy
por: Pliszka, Monika, et al.
Publicado: (2021)

Autophagy Is Pro-Senescence When Seen in Close-Up, but Anti-Senescence in Long-Shot
por: Kwon, Yoojin, et al.
Publicado: (2017)

Focus on Formononetin: Anticancer Potential and Molecular Targets
por: Ong, Samantha Kah Ling, et al.
Publicado: (2019)

Molecular targeted therapy for anticancer treatment
por: Min, Hye-Young, et al.
Publicado: (2022)

Targeting necroptosis in anticancer therapy: mechanisms and modulators
por: Wu, Ying, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_oam7r248incequ0v5rqm4u6evq